Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
NCT06299553 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2024-05-22
Summary
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
Sponsors & Collaborators
-
Advice Pharma Group srl
collaborator INDUSTRY -
Incyte Biosciences Italy S.r.l
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-04
- Primary Completion
- 2025-06-30
- Completion
- 2027-06-30
Countries
- Italy
Study Locations
More Related Trials
-
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
NCT06782789 ·Status: RECRUITING
-
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
NCT00799513 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Indolent Non Follicular Lymphomas Prognostic Project
NCT02904577 ·Status: COMPLETED
-
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT05351593 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NCT07030699 ·Status: WITHDRAWN ·Phase: PHASE2
-
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
NCT02399085 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
NCT04134936 ·Status: COMPLETED ·Phase: PHASE1
-
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT06835530 ·Status: RECRUITING ·Phase: PHASE2
-
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
NCT02955823 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
NCT04974216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT04809467 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)
NCT05746858 ·Status: NOT_YET_RECRUITING
-
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT05883709 ·Status: UNKNOWN
-
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05788289 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
NCT05328102 ·Status: TERMINATED ·Phase: PHASE2
-
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
NCT00907348 ·Status: UNKNOWN ·Phase: PHASE2
-
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
NCT05541341 ·Status: RECRUITING
-
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02142049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
NCT00945724 ·Status: COMPLETED ·Phase: PHASE2